Market revenue in 2024 | USD 313.9 million |
Market revenue in 2030 | USD 456.7 million |
Growth rate | 6.5% (CAGR from 2025 to 2030) |
Largest segment | Calcineurin inhibitors |
Fastest growing segment | Calcineurin Inhibitors |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Calcineurin Inhibitors, Antiproliferative Agents, MTOR Inhibitor, Steroids, Other Drug Classes |
Key market players worldwide | Astellas Pharma Inc, Sanofi SA, Novartis AG ADR, Dr Reddy's Laboratories Ltd ADR, Roche, GlaxoSmithKline, Asahi Kasei Corp, Bristol-Myers Squibb Co, Accord Healthcare, Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to organ transplant immunosuppressant drugs market will help companies and investors design strategic landscapes.
Calcineurin inhibitors was the largest segment with a revenue share of 41.45% in 2024. Horizon Databook has segmented the China organ transplant immunosuppressant drugs market based on calcineurin inhibitors, antiproliferative agents, mtor inhibitor, steroids, other drug classes covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the China organ transplant immunosuppressant drugs market, including forecasts for subscribers. This country databook contains high-level insights into China organ transplant immunosuppressant drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account